Cervical lymphadenopathy presents a shared anatomic challenge for clinicians, yet it serves as the divergent starting point ...

Topline results from a trial evaluating AbbVie and Genmab's epcoritamab to treat a type of lymphoma demonstrated an improvement in progression-free survival, the companies said. AbbVie and Genmab said ...

The U.S. Food and Drug Administration (FDA) has granted full approval of Laverdia, a drug to treat dogs with lymphoma, a type ...

Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...

The FDA has granted full approval to verdinexor tablets (Laverdia; Anivive Lifesciences) for the treatment of dogs with lymphoma. The approval gives veterinarians a promising new oral avenue for ...

For patients who have chronic lymphocytic leukemia (CLL), experiencing Richter transformation with central nervous system ...

Nivolumab plus AVD significantly improves PFS compared to brentuximab vedotin plus AVD in advanced-stage classic Hodgkin lymphoma, with a 91% vs 82% 3-year PFS rate. The PFS benefit of nivolumab plus ...

Company Announcement Based on the topline results from the EPCORE® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced updated efficacy and safety ...

Integration of targeted therapies and immunotherapies offers new hope, enhancing survival rates and quality of life. Patients with mantle cell lymphoma experienced better survival rates when treated ...

Friday afternoon, the company and its partner Genmab shared word that the phase 3 Epcore DLBCL-1 trial missed on its primary ...

AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to ...